Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764905 | 0.86 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL19891802 | 0.86 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL1911601 | 0.82 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL12997895 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL16886922 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL13666789 | 0.80 | L3MBTL1 (0.40) | L3MBTL1 | |
| SCHEMBL18681046 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL5636248 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL21719563 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL21719353 | 0.80 | L3MBTL1 (0.31) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11697652-B2 | Tetracyclic compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697652-B2 | Tetracyclic compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090111824-A1 | AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-11-13 | — | — | US | disclosed |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697652-B2 | Tetracyclic compounds and uses thereof | HAVCR2, PAICS, CCR5 | L3MBTL1 3080/4885 |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | L3MBTL1 4184/4885 |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | L3MBTL1 4731/4885 |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | L3MBTL1 762/4885 |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | L3MBTL1 4671/4885 |
| US-20090111824-A1 | AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | L3MBTL1 4358/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | L3MBTL1 186/4885 |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | TUBB6, MAN2B1, TUBB1 | L3MBTL1 79/4885 |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | TUBB6, TUBB1, TUBA1C | L3MBTL1 122/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | L3MBTL1 4314/4885 |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | L3MBTL1 4671/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | L3MBTL1 4059/4885 |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | L3MBTL1 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.